Shanghai Kehua Bio-Engineering Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Kehua Biotechnology Co., Ltd. (abbreviated as Kehua Biotechnology) was founded in 1981 and listed on the Shenzhen Stock Exchange Small and Medium Sized Board (stock code: 002022. SZ) in 2004. It is an in vitro diagnostic company that integrates research and development, production, and sales, with rich production experience and a complete medical diagnostic product echelon. Kehua Biotechnology is headquartered in Shanghai and has research and production bases in countries and regions such as Italy, Shenzhen, Xi'an, and Suzhou. The company has a national level postdoctoral research workstation (approved by the Ministry of Personnel), Shanghai Enterprise Technology Center, Shanghai Immunodiagnostic Reagent Engineering Technology Research Center, and Shanghai In Vitro Diagnostic Reagent Technology Innovation Center. It is a high-tech enterprise certified by the competent department of Shanghai. Kehua Biotechnology takes research and innovation as the core driving force, creating two major research and development technology platforms for clinical in vitro diagnostic reagents and fully automated detection and analysis instruments, achieving the "serialization" and "integration" of diagnostic reagents and instruments. The company's self-produced products focus on four major sectors: immune diagnosis, biochemical diagnosis, molecular diagnosis, and instant diagnosis (POCT). We have over 260 reagents and instrument products approved by the national drug regulatory department, over 80 domestic products certified by the European Union CE, and some products have also obtained certification and recognition from countries such as the United States and South Korea. At the same time, TGS, an Italian subsidiary of the company, independently owns over 80 CE certified products. Kehua Biotech's business development is based in China and has a global presence. Our products cover more than 30 provinces, cities, and autonomous regions across the country, with over 12000 terminal hospitals, over 500 high industry barrier disease control centers, blood centers/blood stations, and many biopharmaceutical enterprises and research institutes. We have established long-term cooperative relationships with thousands of domestic agents and 18 international agents, and our brand products have been exported to more than 30 countries and regions overseas. The AIDS diagnostic reagent independently developed by the company has obtained the World Health Organization (WHO) PQ certification, and has been listed in the procurement directory by the United Nations Children's Fund (UNICEF), the United States Agency for International Development (USAID) and other organizations and countries. Kehua Biology attaches great importance to the integration of industry, academia, and research. In 2020, it was selected for the Zhangjiang Index and successfully developed a highly sensitive infectious disease screening technology platform. At the same time, we will work together with Fudan University to deepen the cooperation between industry, academia, and research, establish an enterprise innovation center with Fudan Guanghua Lingang, promote the technological integration of Kehua Biology and the Fudan Lingang Industrial Innovation Platform Biomedical Engineering Center, and jointly enhance our technological innovation and industrial integration capabilities. Over the past 40 years since its establishment, Kehua Biotechnology has successively received honorary titles such as "Shanghai Famous Trademark Certificate", "Shanghai Famous Brand", "Shanghai Science and Technology Award (Magnetic Nanomicrospheres Controllable Preparation Technology and Molecular Diagnosis Kit)", "Shanghai Innovative Enterprise", and "Top 100 Innovative Small and Medium sized Enterprises in China". Kehua Biotechnology shoulders the corporate mission of "caring for life and pursuing excellence", with the vision of becoming a pillar in the IVD field. It adheres to the corporate values of "customer first, innovation, collaboration, responsibility, and pragmatism", focuses on the field of in vitro diagnosis, focuses on innovation, lean management, and is committed to contributing to the cause of human health. |
| Headquarter | Shanghai |
| Establish Date | 11/22/1981 |
| Listed Code | 002022.SZ |
| Listed Date | 7/21/2004 |
| Chairman | Ma Zhichao. |
| CEO | Li Ming. |
| Website | www.skhb.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
